In addition, also the PEGGY phase II trial failed in showing any significant clinical benefit from adding pictilisib to paclitaxel in patients with advanced HER2 negative, HR positive BC, in either the ITT population or the PIK3CA mutated subgroup [76]. Here, ERBB2 is linked to breast cancer.